OurotechCancer treatment with certainty

Here’s how breast cancer is being fought today

1st line treatment Herceptin combination

2nd line treatmentT-DM1

3rd line treatmentXeloda

4th line treatmentHormone therapy

Example: HER2+ Breast Cancer

Drug Resistance:Every cancer has a different weakness

The Problem

Multiple drugs target the same cancer subtype but they don’t work on all patients

Tumors can be resistant due to:- Genetic resistance/mutation- Tumor microenvironment- Interaction with other cancer cells- Interaction with healthy cells

Take the guess work out of cancer treatment

The SolutionObtain patient tumor sample from biopsy

Grow tumors in 96 well plate using proprietary hydrogel

Test the effectiveness of drugs and combination treatments

Calculate necessary human dosage from test results

Treat the patient

Obtain patient tumor sample from

biopsy

Grow tumors in 96 well plate using proprietary

hydrogel

Test the effectiveness of drugs and

combination treatments

Calculate necessary human dosage from

test results

Treat the patient

Proof of Concept: IC50

Drug Tested: Doxorubicin

Human IC50: 702nM Ourotech IC50: 600~650nM Alginate IC50: 200nM

IC50: industry standard measure of drug resistanceOurotech can predict this better than the competition

Core Technology

Genesis

Hydrogel that mimics conditions inside patients’ bodies for Stage 3 and 4 breast, colon, and brain cancers

Allows doctors to culture patient tumors outside the body, create 3D tumor models and test drug resistance on patient derived tumors

Market

$500/patient $500M/year

Team

Duleeka Ranatunga, CEO Prof Jonathan Blay Prof Shirley Tang William Lin, Head of R&D

Christina Ryu, Business DevelopmentAli Nikdel, R&DMichael Kim, Head of Finance

Funding Roadmap

Strategic partnership with hospitals for preclinical trials

Strategic partnership with big

pharma client for clinical trials and

distribution

Start generating revenue by

pharmaceutical drug testing services

Optimize product based on drug testing and preclinical results

Seed Series A

Funding and Milestones

Ask: $1.5M Runway: 18 months

Milestones

Finish preclinical trials IRB and begin FDA 510K clearance process

Generate revenues from pharma clients

Develop new prototypes and IP

Traction

2 patents pending 2 academic pilots 2 pharma pilots, sales to start May 2017

1 Pre Clinical Trial In Progress

Partnership for marketing

2 Year Product Development Roadmap

Develop more humanized hydrogels

Integrate hydrogels with microfluidics and bioreactors

Use big data for better drug dosage prediction

Train machine learning algorithms to predict drug resistance

Test immuno- therapies